vs
EXACT SCIENCES CORP（EXAS）与罗布乐思（RBLX）财务数据对比。点击上方公司名可切换其他公司
罗布乐思的季度营收约是EXACT SCIENCES CORP的1.6倍（$1.4B vs $878.4M），EXACT SCIENCES CORP净利率更高（-9.8% vs -22.3%，领先12.5%），罗布乐思同比增速更快（43.2% vs 23.1%），罗布乐思自由现金流更多（$308.6M vs $120.4M），过去两年罗布乐思的营收复合增速更高（32.9% vs 17.4%）
Exact Sciences是总部位于美国威斯康星州麦迪逊的分子诊断企业，专注于早期癌症检测领域。公司核心产品覆盖结直肠癌筛查与预防场景，其中Cologuard是全球首个获批的结直肠癌粪便DNA检测产品，同时还提供其他多种癌症的筛查服务及精准肿瘤检测解决方案。
罗布乐思（Roblox Corporation）是总部位于美国加利福尼亚州圣马特奥的游戏企业，由大卫·巴斯祖奇与埃里克·卡塞尔于2004年共同创立。公司核心产品为同名线上游戏创作平台Roblox，于2006年正式上线，截至2024年12月底全球员工规模已超2400人。
EXAS vs RBLX — 直观对比
营收规模更大
RBLX
是对方的1.6倍
$878.4M
营收增速更快
RBLX
高出20.1%
23.1%
净利率更高
EXAS
高出12.5%
-22.3%
自由现金流更多
RBLX
多$188.1M
$120.4M
两年增速更快
RBLX
近两年复合增速
17.4%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $878.4M | $1.4B |
| 净利润 | $-86.0M | $-316.0M |
| 毛利率 | 70.1% | 77.7% |
| 营业利润率 | -9.4% | -25.3% |
| 净利率 | -9.8% | -22.3% |
| 营收同比 | 23.1% | 43.2% |
| 净利润同比 | 90.1% | -43.9% |
| 每股收益（稀释后） | $-0.45 | $-0.44 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EXASRBLX
| Q4 25 | $878.4M | $1.4B | ||
| Q3 25 | $850.7M | $1.4B | ||
| Q2 25 | $811.1M | $1.1B | ||
| Q1 25 | $706.8M | $1.0B | ||
| Q4 24 | $713.4M | $988.2M | ||
| Q3 24 | $708.7M | $919.0M | ||
| Q2 24 | $699.3M | $893.5M | ||
| Q1 24 | $637.5M | $801.3M |
净利润EXASRBLX
| Q4 25 | $-86.0M | $-316.0M | ||
| Q3 25 | $-19.6M | $-255.6M | ||
| Q2 25 | $-1.2M | $-278.4M | ||
| Q1 25 | $-101.2M | $-215.1M | ||
| Q4 24 | $-864.6M | $-219.6M | ||
| Q3 24 | $-38.2M | $-239.3M | ||
| Q2 24 | $-15.8M | $-205.9M | ||
| Q1 24 | $-110.2M | $-270.6M |
毛利率EXASRBLX
| Q4 25 | 70.1% | 77.7% | ||
| Q3 25 | 68.6% | 78.2% | ||
| Q2 25 | 69.3% | 78.2% | ||
| Q1 25 | 70.8% | 78.3% | ||
| Q4 24 | 69.0% | 77.9% | ||
| Q3 24 | 69.4% | 77.7% | ||
| Q2 24 | 69.8% | 77.8% | ||
| Q1 24 | 70.0% | 77.7% |
营业利润率EXASRBLX
| Q4 25 | -9.4% | -25.3% | ||
| Q3 25 | -3.0% | -21.8% | ||
| Q2 25 | -0.3% | -29.8% | ||
| Q1 25 | -13.6% | -24.6% | ||
| Q4 24 | -122.8% | -24.7% | ||
| Q3 24 | -5.6% | -30.4% | ||
| Q2 24 | -3.8% | -26.6% | ||
| Q1 24 | -16.7% | -37.7% |
净利率EXASRBLX
| Q4 25 | -9.8% | -22.3% | ||
| Q3 25 | -2.3% | -18.8% | ||
| Q2 25 | -0.1% | -25.8% | ||
| Q1 25 | -14.3% | -20.8% | ||
| Q4 24 | -121.2% | -22.2% | ||
| Q3 24 | -5.4% | -26.0% | ||
| Q2 24 | -2.3% | -23.0% | ||
| Q1 24 | -17.3% | -33.8% |
每股收益（稀释后）EXASRBLX
| Q4 25 | $-0.45 | $-0.44 | ||
| Q3 25 | $-0.10 | $-0.37 | ||
| Q2 25 | $-0.01 | $-0.41 | ||
| Q1 25 | $-0.54 | $-0.32 | ||
| Q4 24 | $-4.69 | $-0.32 | ||
| Q3 24 | $-0.21 | $-0.37 | ||
| Q2 24 | $-0.09 | $-0.32 | ||
| Q1 24 | $-0.60 | $-0.43 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $964.7M | $3.1B |
| 总债务越低越好 | — | $1.2B |
| 股东权益账面价值 | $2.4B | $394.5M |
| 总资产 | $5.9B | $9.6B |
| 负债/权益比越低杠杆越低 | — | 2.98× |
8季度趋势，按日历期对齐
现金及短期投资EXASRBLX
| Q4 25 | $964.7M | $3.1B | ||
| Q3 25 | $1.0B | $2.9B | ||
| Q2 25 | $858.4M | $2.6B | ||
| Q1 25 | $786.2M | $2.7B | ||
| Q4 24 | $1.0B | $2.4B | ||
| Q3 24 | $1.0B | $2.3B | ||
| Q2 24 | $946.8M | $2.4B | ||
| Q1 24 | $652.1M | $2.4B |
总债务EXASRBLX
| Q4 25 | — | $1.2B | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $1.2B | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益EXASRBLX
| Q4 25 | $2.4B | $394.5M | ||
| Q3 25 | $2.5B | $407.6M | ||
| Q2 25 | $2.5B | $353.2M | ||
| Q1 25 | $2.4B | $310.7M | ||
| Q4 24 | $2.4B | $221.4M | ||
| Q3 24 | $3.2B | $189.9M | ||
| Q2 24 | $3.2B | $121.5M | ||
| Q1 24 | $3.1B | $71.6M |
总资产EXASRBLX
| Q4 25 | $5.9B | $9.6B | ||
| Q3 25 | $5.9B | $8.6B | ||
| Q2 25 | $5.8B | $7.8B | ||
| Q1 25 | $5.7B | $7.5B | ||
| Q4 24 | $5.9B | $7.2B | ||
| Q3 24 | $6.7B | $6.7B | ||
| Q2 24 | $6.7B | $6.5B | ||
| Q1 24 | $6.4B | $6.3B |
负债/权益比EXASRBLX
| Q4 25 | — | 2.98× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 5.48× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $151.7M | $607.0M |
| 自由现金流经营现金流 - 资本支出 | $120.4M | $308.6M |
| 自由现金流率自由现金流/营收 | 13.7% | 21.8% |
| 资本支出强度资本支出/营收 | 3.6% | 21.1% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $356.8M | $1.4B |
8季度趋势，按日历期对齐
经营现金流EXASRBLX
| Q4 25 | $151.7M | $607.0M | ||
| Q3 25 | $219.9M | $546.2M | ||
| Q2 25 | $89.0M | $199.3M | ||
| Q1 25 | $30.8M | $443.9M | ||
| Q4 24 | $47.1M | $184.5M | ||
| Q3 24 | $138.7M | $247.4M | ||
| Q2 24 | $107.1M | $151.4M | ||
| Q1 24 | $-82.3M | $238.9M |
自由现金流EXASRBLX
| Q4 25 | $120.4M | $308.6M | ||
| Q3 25 | $190.0M | $443.6M | ||
| Q2 25 | $46.7M | $176.7M | ||
| Q1 25 | $-365.0K | $426.5M | ||
| Q4 24 | $10.7M | $120.6M | ||
| Q3 24 | $112.6M | $218.0M | ||
| Q2 24 | $71.2M | $111.7M | ||
| Q1 24 | $-120.0M | $192.3M |
自由现金流率EXASRBLX
| Q4 25 | 13.7% | 21.8% | ||
| Q3 25 | 22.3% | 32.6% | ||
| Q2 25 | 5.8% | 16.3% | ||
| Q1 25 | -0.1% | 41.2% | ||
| Q4 24 | 1.5% | 12.2% | ||
| Q3 24 | 15.9% | 23.7% | ||
| Q2 24 | 10.2% | 12.5% | ||
| Q1 24 | -18.8% | 24.0% |
资本支出强度EXASRBLX
| Q4 25 | 3.6% | 21.1% | ||
| Q3 25 | 3.5% | 7.5% | ||
| Q2 25 | 5.2% | 2.1% | ||
| Q1 25 | 4.4% | 1.7% | ||
| Q4 24 | 5.1% | 6.5% | ||
| Q3 24 | 3.7% | 3.2% | ||
| Q2 24 | 5.1% | 4.4% | ||
| Q1 24 | 5.9% | 5.8% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EXAS
| Screening | $695.1M | 79% |
| Precision Oncology | $183.2M | 21% |
RBLX
暂无分部数据
